ReviewSeminars in respiratory and critical care medicine2018
Epidemiology of Nontuberculous Mycobacteriosis.
Review in Seminars in respiratory and critical care medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 96 citations in OpenAlex.
- Population Pharmacokinetic Analysis of Bedaquiline-Clarithromycin for Dose Selection Against Pulmonary Nontuberculous Mycobacteria Based on a Phase 1, Randomized, Pharmacokinetic Study.Journal of clinical pharmacology · 2021Trial
- Targeting nontuberculous mycobacteria with phages: optimization of in vitro host range assays.BMC microbiology · 2026Article
- Hospital Environment-Associated Sources of Mycobacterium abscessus Infection in Transplant Recipients.JAMA network open · 2026Article
- Mycobacterium intracellulare Infection in a Japanese Patient with Signal Transducer and Activator of Transcription-3 Gain-of-function Syndrome.Internal medicine (Tokyo, Japan) · 2026Article
- Strain-dependent disease progression and necrotizing granuloma formation in a murine model induced by virulent strains ofMicrobiology spectrum · 2026Article
- Epidemiology of Healthcare Facility-Associated Nontuberculous Mycobacteria From 2012 Through 2020 in a 10-Hospital Network in the United States.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Patient's features, clinical patterns and outcomes of non-tuberculous mycobacteria infections: A 10-year retrospective analysis from a third level university hospital.Journal of clinical tuberculosis and other mycobacterial diseases · 2026Article
- QcrB inhibitor Q203 (Telacebec) can synergize with clofazimine and clarithromycin to control a Mycobacterium avium infection.PloS one · 2026Article
- Differential roles of resident lung macrophages during control of murine alveolar and airwayFrontiers in tuberculosis · 2026Article
- Review of the Canadian Nontuberculous Mycobacterial Disease Landscape-Challenges and Opportunities.Tropical medicine and infectious disease · 2025Review
- Clinical efficacy of sitafloxacin-containing regimens for Mycobacterium avium complex pulmonary disease.BMC pulmonary medicine · 2025Article
- How do climate conditions and urbanisation impact nontuberculous mycobacterial infections? An Italian nationwide case-control study.ERJ open research · 2025Article
- Subacute Mastoiditis Without Verified Nontuberculous Mycobacteria-Still a Clinical Challenge.Laryngoscope investigative otolaryngology · 2025Article
- The efficacy of a regimen comprising clarithromycin, clofazimine, and bedaquiline in a mouse model of chronicAntimicrobial agents and chemotherapy · 2025Article
- Systemic absorption of liposomal inhaled amikacin in the treatment of resistantRevista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2025Article
- Article
- Regimen comprising clarithromycin, clofazimine and bedaquiline is more efficacious than monotherapy in a mouse model of chronicbioRxiv : the preprint server for biology · 2024Article
- Epidemiology of nontuberculous mycobacteria in the Finger Lakes region of New York.Journal of clinical tuberculosis and other mycobacterial diseases · 2024Article
- A Narrative Review of Bedaquiline and Delamanid: New Arsenals Against Multidrug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis.Journal of clinical laboratory analysis · 2024Review
- Phenotypical characteristics of nontuberculous mycobacterial infection in patients with bronchiectasis.Respiratory research · 2024Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Annual prevalence estimates for pulmonary nontuberculous mycobacterial (PNTM) disease in the contiguous United States range from 1.4 to 13.9 per 100,000 persons, while one study found an annual prevalence of up to 44 per 100,000 persons in Hawaii. PNTM prevalence varies by region, sex, and race/ethnicity, with higher prevalence among women and persons of Asian ancestry, as well as in the Southern United States and Hawaii. Studies consistently indicate that PNTM prevalence is increasing, with estimates ranging from 2.5 to 8% per year. Most PNTM disease is associated with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.